<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id>
      <journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id>
      <journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id>
      <journal-title-group>
        <journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1234-1010</issn>
      <issn pub-type="epub">1643-3750</issn>
      <publisher>
        <publisher-name>International Scientific Literature, Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21525816</article-id>
      <article-id pub-id-type="pmc">3539579</article-id>
      <article-id pub-id-type="doi">10.12659/MSM.881753</article-id>
      <article-id pub-id-type="publisher-id">881753</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Study</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ciurzy&#x144;ski</surname>
            <given-names>Micha&#x142;</given-names>
          </name>
          <xref ref-type="aff" rid="af1-medscimonit-17-5-cs56">1</xref>
          <xref ref-type="author-notes" rid="fn1-medscimonit-17-5-cs56">A</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
          <xref ref-type="author-notes" rid="fn5-medscimonit-17-5-cs56">E</xref>
          <xref ref-type="author-notes" rid="fn6-medscimonit-17-5-cs56">F</xref>
          <xref ref-type="author-notes" rid="fn7-medscimonit-17-5-cs56">G</xref>
          <xref ref-type="corresp" rid="c1-medscimonit-17-5-cs56"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jankowski</surname>
            <given-names>Krzysztof</given-names>
          </name>
          <xref ref-type="aff" rid="af1-medscimonit-17-5-cs56">1</xref>
          <xref ref-type="author-notes" rid="fn1-medscimonit-17-5-cs56">A</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
          <xref ref-type="author-notes" rid="fn5-medscimonit-17-5-cs56">E</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pietrzak</surname>
            <given-names>Bronis&#x142;awa</given-names>
          </name>
          <xref ref-type="aff" rid="af2-medscimonit-17-5-cs56">2</xref>
          <xref ref-type="author-notes" rid="fn1-medscimonit-17-5-cs56">A</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
          <xref ref-type="author-notes" rid="fn5-medscimonit-17-5-cs56">E</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mazanowska</surname>
            <given-names>Natalia</given-names>
          </name>
          <xref ref-type="aff" rid="af2-medscimonit-17-5-cs56">2</xref>
          <xref ref-type="author-notes" rid="fn1-medscimonit-17-5-cs56">A</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
          <xref ref-type="author-notes" rid="fn5-medscimonit-17-5-cs56">E</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rzewuska</surname>
            <given-names>Ewa</given-names>
          </name>
          <xref ref-type="aff" rid="af1-medscimonit-17-5-cs56">1</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kowalik</surname>
            <given-names>Robert</given-names>
          </name>
          <xref ref-type="aff" rid="af3-medscimonit-17-5-cs56">3</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pruszczyk</surname>
            <given-names>Piotr</given-names>
          </name>
          <xref ref-type="aff" rid="af1-medscimonit-17-5-cs56">1</xref>
          <xref ref-type="author-notes" rid="fn1-medscimonit-17-5-cs56">A</xref>
          <xref ref-type="author-notes" rid="fn2-medscimonit-17-5-cs56">B</xref>
          <xref ref-type="author-notes" rid="fn3-medscimonit-17-5-cs56">C</xref>
          <xref ref-type="author-notes" rid="fn4-medscimonit-17-5-cs56">D</xref>
          <xref ref-type="author-notes" rid="fn5-medscimonit-17-5-cs56">E</xref>
          <xref ref-type="author-notes" rid="fn6-medscimonit-17-5-cs56">F</xref>
          <xref ref-type="author-notes" rid="fn7-medscimonit-17-5-cs56">G</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-medscimonit-17-5-cs56"><label>1</label>Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland</aff>
      <aff id="af2-medscimonit-17-5-cs56"><label>2</label>Department of Obstetrics and Gynaecology, Medical University of Warsaw, Warsaw, Poland</aff>
      <aff id="af3-medscimonit-17-5-cs56"><label>3</label>Department of Cardiology, Medical University of Warsaw, Warsaw, Poland</aff>
      <author-notes>
        <corresp id="c1-medscimonit-17-5-cs56">Micha&#x142; Ciurzy&#x144;ski, Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland, e-mail: <email>michal.ciurzynski@wum.edu.pl</email></corresp>
        <fn id="fn1-medscimonit-17-5-cs56">
          <label>A</label>
          <p>Study Design</p>
        </fn>
        <fn id="fn2-medscimonit-17-5-cs56">
          <label>B</label>
          <p>Data Collection</p>
        </fn>
        <fn id="fn3-medscimonit-17-5-cs56">
          <label>C</label>
          <p>Statistical Analysis</p>
        </fn>
        <fn id="fn4-medscimonit-17-5-cs56">
          <label>D</label>
          <p>Data Interpretation</p>
        </fn>
        <fn id="fn5-medscimonit-17-5-cs56">
          <label>E</label>
          <p>Manuscript Preparation</p>
        </fn>
        <fn id="fn6-medscimonit-17-5-cs56">
          <label>F</label>
          <p>Literature Search</p>
        </fn>
        <fn id="fn7-medscimonit-17-5-cs56">
          <label>G</label>
          <p>Funds Collection</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>17</volume>
      <issue>5</issue>
      <fpage>CS56</fpage>
      <lpage>CS59</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>6</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>10</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Med Sci Monit, 2011</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license>
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <sec>
          <title>Background</title>
          <p>A serious complication of heparin treatment, heparin-induced thrombocytopenia (HIT) is rarely observed in pregnant women. Drug therapy during pregnancy should always be chosen to minimize fetal risk. The management of HIT in pregnancy represents a medical challenge. Unlike heparins, the anticoagulants used in patients with HIT do cross the placenta, with unknown fetal effects.</p>
        </sec>
        <sec>
          <title>Case Report</title>
          <p>We present a case of a 24-year-old female presenting for care at 34 weeks of gestation with acute pulmonary embolism treated initially with unfractionated heparin (UFH) and low molecular weight heparin (LMWH), who developed HIT. She was then successfully treated with fondaparinux.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>To the best of our knowledge, this is one of the first case reports describing a successful use of fondaparinux in the treatment of HIT in a third-trimester pregnant woman, providing a novel approach for this subset of patients.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>heparin-induced thrombocytopenia</kwd>
        <kwd>pulmonary embolism</kwd>
        <kwd>pregnancy</kwd>
        <kwd>fondaparinux</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>During pregnancy and the postpartum period, women are 4 times more likely to suffer from venous thromboembolism (VTE) than if they are not pregnant [<xref ref-type="bibr" rid="b1-medscimonit-17-5-cs56">1</xref>]. The incidence of pulmonary embolism (PE) during pregnancy ranges between 0.3 and 1 per 1000 deliveries, and PE is a leading cause of the maternal mortality in developed countries [<xref ref-type="bibr" rid="b2-medscimonit-17-5-cs56">2</xref>,<xref ref-type="bibr" rid="b3-medscimonit-17-5-cs56">3</xref>]. Heparin- induced thrombocytopenia (HIT) is an immune-mediated disorder caused by the development of antibodies to a complex of platelet factor 4 (PF4) and heparin. HIT antibodies of IgG class bind to a multimolecular complex of PF4 and heparin on platelet surfaces, resulting in platelet activation. HIT is reported to be extremely rare in pregnant women. We present a case of a pregnant patient with acute PE treated initially with unfractionated heparin (UFH) and low molecular weight heparin (LMWH), who developed HIT. She was then successfully treated with fondaparinux until delivery.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 24-year-old female (gravida 1, para 1) at 34 weeks of gestation was referred from another hospital to the Intensive Care Unit due to acute PE. One month before the hospitalization, the patient was prescribed bed-rest due to threatened premature labour. Several days before admission, she fainted and experienced severe dyspnoea. Spiral computed tomography performed in a regional hospital detected bilateral proximal pulmonary artery thromboemboli. Transthoracic echocardiography revealed right ventricular dysfunction &#x2013; enlarged right ventricle (33 mm), paradoxical movement of the intraventricular septum, McConnell sign, shortened acceleration time (50 ms) and a transtricuspid pressure gradient value of 30 mmHg. Moreover, saddle pulmonary embolus was revealed (<xref ref-type="fig" rid="f1-medscimonit-17-5-cs56">Figure 1</xref>). On admission to the Intensive Care Unit, she was moderately dyspneic, with preserved systemic blood pressure (110/70 mmHg) and moderate tachycardia 98/min. D-dimer plasma level was 5226 &#x3BC;g/ml (normal values &lt;500 &#x3BC;g/ml, Vidas Bio-Merieux), while plasma cardiac troponin level and renal and hepatic functions were normal. Therefore, a diagnosis of intermediate-risk acute PE was made. Initially, for 4 days the patient was treated with APTT adjusted intravenous infusion of unfractionated heparin (UFH) followed by a 2-day treatment with enoxaparin in a dose of 1 mg/kg. The initial platelet count was 200&#xD7;10<sup>9</sup>/L. Platelet count was monitored every other day during the first days of therapy and always exceeded 100&#xD7;10<sup>9</sup>/L. However, on the seventh day of anticoagulation therapy, a rapid decline in the platelet count, reaching 44&#xD7;10<sup>9</sup>/L, was observed. LMWH was stopped immediately. The following causes of thrombocytopenia in our pregnant patient were considered: heparin-induced thrombocytopenia (HIT), thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), preeclampsia-eclampsia and HELLP syndrome. HIT was diagnosed on the basis of antiplatelet-heparin binding antibodies presence in serum (GTI Diagnostics&#x2019; PF4 Enhanced Solid Phase ELISA), while other causes were excluded. Treatment with subcutaneous fondaparinux injections in a daily dose of 7.5 mg was commenced. Over the next few days, the platelet count decreased further, with a nadir of 19&#xD7;10<sup>9</sup>/L. However, after 10 days the platelet count started to increase progressively (<xref ref-type="fig" rid="f2-medscimonit-17-5-cs56">Figure 2</xref>). No recurrence of venous thromboembolism or bleeding occurred. At 37 weeks of gestation, 24 hours before an elective caesarean delivery, fondaparinux injections were discontinued. At that time, platelet count was 200&#xD7;10<sup>9</sup>/L and no signs of right ventricular dysfunction were present on echocardiography. The patient successfully underwent an elective caesarean section under general anesthesia and a healthy female newborn weighting 2620 g was delivered. The course of the surgery was uneventful and no excessive bleeding was observed. Peritoneal drainage and skin closure with interrupted sutures were used as precautionary measures. The newborn suffered from no complications and had a normal platelet count (201 to 313&#xD7;10<sup>9</sup>L).</p>
      <p>On the first postoperative day, daily fondaparinux injections of 7.5 mg were reintroduced. One day later, the first dose of warfarin was administered and fondaparinux was discontinued 8 days later when a therapeutic INR was maintained between 2 and 3. Both mother and baby were discharged home in good general condition on the 10<sup>th</sup> day after delivery.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>VTE in pregnancy is an important cause of maternal morbidity, and acute PE still remains the major cause of maternal mortality in the developed countries [<xref ref-type="bibr" rid="b4-medscimonit-17-5-cs56">4</xref>]. The treatment of acute PE in pregnancy routinely relies on the use of LMWH or UFH. On admission to the hospital, the patient was normotensive, although echocardiographic signs of right ventricular dysfunction were present. According to the recent ESC guidelines on the diagnosis and management of acute pulmonary embolism, our patient suffered from intermediate-risk PE (with a reported short-term mortality of 3&#x2013;15%) [<xref ref-type="bibr" rid="b5-medscimonit-17-5-cs56">5</xref>]. Anticoagulation with intravenous UFH was initiated, due mainly to fear of possible hemodynamic deterioration, which might have then required thrombolysis or surgical embolectomy. After 4 days of UHF infusion, the patient&#x2019;s hemodynamic status stabilized. Full-dose subcutaneous enoxaparin injections were then started. After 7 days of heparin therapy, the platelet count rapidly decreased from an initial value of 200&#xD7;10<sup>9</sup>/L to 44&#xD7;10<sup>9</sup>/L, and HIT was suspected.</p>
      <p>Currently, HIT is diagnosed by the combination of clinical observations and laboratory results. According to the 8th ACCP guidelines on Antithrombotic and Thrombolytic Therapy, diagnosis of HIT should be made when any of the following events occur in association with the presence of &#x201C;HIT antibodies&#x201D; detected by <italic>in vitro</italic> assays: an otherwise unexplained platelet count fall of &#x2265;50%, venous or arterial thrombosis, skin lesions at heparin injection sites, or acute systemic (anaphylactoid) reaction, that occur after iv heparin bolus administration [<xref ref-type="bibr" rid="b6-medscimonit-17-5-cs56">6</xref>]. PF4 ENHANCED enzyme-linked immunosorbent assay confirmed HIT antibodies in the studied patient. It should be noted that we did not perform (14)C-serotonin-release assay, which is regarded for reference method in HIT diagnosis. This test is not widely used in routine clinical practise and was unavailable in our department.</p>
      <p>HIT is a rare, but serious side effect, leading to paradoxical thromboembolism. Previous studies have shown that the risk of HIT is lower with LMWH than with UFH, which is more immunogenic, and this condition is extremely rare in pregnant patients [<xref ref-type="bibr" rid="b7-medscimonit-17-5-cs56">7</xref>]. Only 1 possible case of HIT was observed among 1167 pregnancies treated with LMWH in 3 studies [<xref ref-type="bibr" rid="b8-medscimonit-17-5-cs56">8</xref>&#x2013;<xref ref-type="bibr" rid="b10-medscimonit-17-5-cs56">10</xref>]. Moreover, Greer and Nielson-Piercy reported no HIT cases among 2777 pregnancies in which LMWH was administered [<xref ref-type="bibr" rid="b11-medscimonit-17-5-cs56">11</xref>].</p>
      <p>Although patients with HIT can have significantly decreased platelet counts, they still require anticoagulation with an effective antithrombotic agent that does not cross-react <italic>in vivo</italic> with the circulating anti-heparin/PF4 antibodies. Moreover, administration of drug therapy during pregnancy should be very careful to minimise fetal risks. An alternative non-heparin anticoagulant that may be used during pregnancy is danaparoid, which does not appear to cross the placenta [<xref ref-type="bibr" rid="b12-medscimonit-17-5-cs56">12</xref>&#x2013;<xref ref-type="bibr" rid="b14-medscimonit-17-5-cs56">14</xref>]. Anticoagulation with danaparoid in 2 pregnancies was reported by Schindewolf and Lindhoff-Last [<xref ref-type="bibr" rid="b15-medscimonit-17-5-cs56">15</xref>]. We didn&#x2019;t use danaparoid because this drug was not available in our hospital and it was impossible to use it quickly. Mehta et al described a case of HIT at 7 weeks gestation managed with lepirudin. This agent, however, can cross the placenta [<xref ref-type="bibr" rid="b16-medscimonit-17-5-cs56">16</xref>]. Young et al described a pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for suspected HIT during the third trimester, but there exists only limited human data describing use of this agent during pregnancy [<xref ref-type="bibr" rid="b17-medscimonit-17-5-cs56">17</xref>]. Fondaparinux is another potential therapeutic option for HIT. Fondaparinux offers practical advantages over direct thrombin inhibitors, including once-daily subcutaneous administration, and has no requirement for laboratory monitoring. However, 1 study found that approximately 10% of the maternal plasma concentration of fondaparinux could be detected in the cord blood of a newborn [<xref ref-type="bibr" rid="b18-medscimonit-17-5-cs56">18</xref>]. Dempfle et al. found transplacental passage of fondaparinux in 5 women, who were treated because of heparin allergy, although this concentration was well below that required for effective anticoagulation, and no adverse effects were noted in the newborns [<xref ref-type="bibr" rid="b19-medscimonit-17-5-cs56">19</xref>]. Furthermore, Lagrange et al observed no transplacental passage of fondaparinux in an <italic>in vitro</italic> study [<xref ref-type="bibr" rid="b20-medscimonit-17-5-cs56">20</xref>]. Finally, Mazollai et al suggest that fondaparinux is a safe and effective treatment in pregnant patients [<xref ref-type="bibr" rid="b21-medscimonit-17-5-cs56">21</xref>]. Importantly, fondaparinux does not cross-react <italic>in vivo</italic> with the circulating anti-heparin/PF4 antibodies, although 1 non-pregnant patient treated with fondaparinux is reported to have developed HIT antibodies in the absence of heparin administration [<xref ref-type="bibr" rid="b22-medscimonit-17-5-cs56">22</xref>].</p>
      <p>Since transplacental passage of fondaparinux cannot be excluded, it was decided to perform an elective caesarean delivery in order to minimise the risk of bleeding complications in the newborn during delivery (i.e., intracranial hemorrhage). Moreover, the patient was scheduled for an elective caesarean section because she was diagnosed earlier with threatened preterm labour and had recurrent contractions causing shortening of the cervix. There was considerable concern that it would be necessary to perform an urgent caesarean section without prior discontinuation of fondaparinux, with high risk of bleeding during the surgery. Therefore it was decided to perform an elective caesarean section after the 37<sup>th</sup> week of gestation. We decided to use general anaesthesia due to lack of experience with fondaparinux and regional anesthesia with the possibility of bleeding complications after neuraxial analgesia. The half-life of fondaparinux is 17&#x2013;21 h, which means that catheter placement would be possible at least 40 hours (three elimination half-lives) after the last dose of fondaparinux.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>We believe fondaparinux to be the anticoagulant of choice in rare cases of HIT during the antepartum period. To the best of our knowledge, this is one of the first case reports describing the successful use of fondaparinux in the treatment of HIT in a third-trimester pregnant woman, providing a novel approach for this subset of patients.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn8-medscimonit-17-5-cs56">
        <p><bold>Source of support:</bold> Departmental sources</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-medscimonit-17-5-cs56">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heit</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kobbervig</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>AH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population based study</article-title>
          <source>Ann Intern Med</source>
          <year>2005</year>
          <volume>36</volume>
          <fpage>697</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="pmid">16287790</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-medscimonit-17-5-cs56">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rutherford</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Deep venous thrombosis and pulmonary embolism in pregnancy</article-title>
          <source>Obstet Gynecol Clin North Am</source>
          <year>1991</year>
          <volume>18</volume>
          <fpage>345</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">1945260</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-medscimonit-17-5-cs56">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sullivan</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Slaytor</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Maternal mortality in Australia, 1973&#x2013;1996</article-title>
          <source>Aust N Z J Obstet Gynaecol</source>
          <year>2004</year>
          <volume>44</volume>
          <fpage>452</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">15387869</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-medscimonit-17-5-cs56">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bates</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Greer</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Pabinger</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy</article-title>
          <source>Chest</source>
          <year>2008</year>
          <volume>133</volume>
          <issue>Suppl 6</issue>
          <fpage>844S</fpage>
          <lpage>886S</lpage>
          <pub-id pub-id-type="pmid">18574280</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-medscimonit-17-5-cs56">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torbicki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perrier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Konstantinides</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines on the diagnosis and management of acute pulmonary embolism</article-title>
          <source>Eur Heart J</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>2276</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">18757870</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-medscimonit-17-5-cs56">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lincoff</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physician Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition)</article-title>
          <source>Chest</source>
          <year>2008</year>
          <volume>133</volume>
          <fpage>340S</fpage>
          <lpage>80S</lpage>
          <pub-id pub-id-type="pmid">18574270</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-medscimonit-17-5-cs56">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin</article-title>
          <source>N Eng J Med</source>
          <year>1995</year>
          <volume>332</volume>
          <fpage>1330</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="b8-medscimonit-17-5-cs56">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanson</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Lensing</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Prins</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of low-molecular-weight heparin in pregnancy: a systemic review</article-title>
          <source>Thromb Haemost</source>
          <year>1999</year>
          <volume>81</volume>
          <fpage>668</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">10365733</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-medscimonit-17-5-cs56">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lepercq</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Conrad</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Borel-Derlon</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies</article-title>
          <source>Br J Obstet Gynaecol</source>
          <year>2001</year>
          <volume>108</volume>
          <fpage>1134</fpage>
          <lpage>40</lpage>
        </element-citation>
      </ref>
      <ref id="b10-medscimonit-17-5-cs56">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ellison</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Greer</surname>
              <given-names>IA</given-names>
            </name>
          </person-group>
          <article-title>Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy</article-title>
          <source>Br J Obstet Gynaecol</source>
          <year>2000</year>
          <volume>107</volume>
          <fpage>1116</fpage>
          <lpage>21</lpage>
        </element-citation>
      </ref>
      <ref id="b11-medscimonit-17-5-cs56">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greer</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Nelson-Piercy</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>401</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">15811953</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-medscimonit-17-5-cs56">
        <label>12</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>HN</given-names>
            </name>
          </person-group>
          <article-title>Danaparoid for the treatment of heparin-induced thrombocytopenia</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Heparin-induced thrombocytopenia</source>
          <edition>4Pth ed</edition>
          <publisher-loc>New York, NY</publisher-loc>
          <publisher-name>Informa Healthcare USA</publisher-name>
          <year>2007</year>
          <fpage>319</fpage>
          <lpage>43</lpage>
        </element-citation>
      </ref>
      <ref id="b13-medscimonit-17-5-cs56">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magnani</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Gallus</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia (HIT): a roport of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004</article-title>
          <source>Thromb Haemost</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>967</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">16732376</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-medscimonit-17-5-cs56">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Myers</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Westby</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopenia-positive skin reaction</article-title>
          <source>Blood Coagul Fibrynolysis</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>485</fpage>
          <lpage>87</lpage>
        </element-citation>
      </ref>
      <ref id="b15-medscimonit-17-5-cs56">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindewolf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lindhoff-Last</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses</article-title>
          <source>Thromb Haemost</source>
          <year>2008</year>
          <volume>99</volume>
          <fpage>776</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">18392337</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-medscimonit-17-5-cs56">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Golichowski</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy</article-title>
          <source>J Thromb Haemost</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>1665</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">15333046</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-medscimonit-17-5-cs56">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Al-Mandhiry</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Vaida</surname>
              <given-names>ST</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Successful use of argatroban during the third-trimester of pregnancy: case report and review of literature</article-title>
          <source>Pharmacotherapy</source>
          <year>2009</year>
          <volume>28</volume>
          <fpage>1532</fpage>
          <lpage>36</lpage>
        </element-citation>
      </ref>
      <ref id="b18-medscimonit-17-5-cs56">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harenberg</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy</article-title>
          <source>Thromb Res</source>
          <year>2007</year>
          <volume>119</volume>
          <fpage>385</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">16647746</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-medscimonit-17-5-cs56">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dampfle</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Minor transplacental passage of fondaparinux <italic>in vivo</italic></article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>1914</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">15115845</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-medscimonit-17-5-cs56">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lagrange</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brun</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Vergnes</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fondaparinux sodium does not cross the placental barrier: study using the <italic>in vitro</italic> human dually perfused cotyledon model</article-title>
          <source>Clin Pharmacokinet</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>47</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">12383045</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-medscimonit-17-5-cs56">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzolai</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hohlfeld</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Spertini</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <fpage>1569</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">16645165</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-medscimonit-17-5-cs56">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Aster</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia associated with fondaparinux</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>356</volume>
          <fpage>2653</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">17582083</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-medscimonit-17-5-cs56" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Transthoracic echocardiography showing saddle pulmonary thromboembolus.</p>
      </caption>
      <graphic xlink:href="medscimonit-17-5-CS56-g001"/>
    </fig>
    <fig id="f2-medscimonit-17-5-cs56" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Medication history. Arrow indicate the day of fondaparinux administration.</p>
      </caption>
      <graphic xlink:href="medscimonit-17-5-CS56-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
